PARP inhibitors in cancer therapy: Magic bullets but moving targets

Frontiers in Oncology

Volumn 3 NOV, Issue , 2013, Pages

  Shah, Girish M ^a   Robu, Mihaela ^a   Purohit, Nupur K ^a   Rajawat, Jyotika ^a   Tentori, Lucio ^b   Graziani, Grazia ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

BRCA mutant cancers; Cancer therapy; Combination therapy; Multiple targets of PARPi; PARP inhibitors (PARPi); Poly(ADP ribose) polymerase (PARP); Synthetic lethality

Indexed keywords

BRCA2 PROTEIN; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN;

ARTICLE; CANCER THERAPY; DNA DAMAGE; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENOMIC INSTABILITY; HUMAN; PROTEIN EXPRESSION; RECOMBINATION REPAIR; SINGLE STRANDED DNA BREAK; UPREGULATION;

EID: 84891044156     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00279     Document Type: Article

References (41)

1. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 34(6):1217-56. doi:10.1016/j.mam.2013.01.006
2. Do K, Chen AP. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res (2013) 19(5):977-84. doi:10.1158/1078-0432.CCR-12-0163
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-7. doi:10.1038/nature03443
4. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434(7035):917-21. doi:10.1038/nature03445
5. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 5(4):387-93. doi:10.1016/j.molonc.2011.07.001
6. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol (2013) 3:228. doi:10.3389/fonc.2013.00228
7. Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, et al. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. Cancer Chemother Pharmacol (2013) 72(1):117-25. doi:10.1007/s00280-013-2175-0
8. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol (2012) 13(7):411-24. doi:10.1038/nrm3376
9. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev (2012) 26(5):417-32. doi:10.1101/gad.183509.111
10. Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-inhibitors in cancer therapy. Front Pharmacol (2013) 4:18. doi:10.3389/fphar.2013.00018
11. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature (2012) 481(7381):287-94. doi:10.1038/nature10760
12. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res (2012) 72(21):5588-99. doi:10.1158/0008-5472.CAN-12-2753
13. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 108(8):3406-11. doi:10.1073/pnas.1013715108
14. Somlo G, Frankel PH, Luu TH, Ma C, Arun B, Garcia A, et al. Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer. J Clin Oncol (2013) 31(15-Suppl):1024.
15. Dey N, Sun Y, Carlson J, Friedman L, De P, Leyland-Jones B. A combination of dual PI3K-mTOR inhibitor, GDC-0980, with PARP inhibitor plus carboplatin blocked tumor growth of BRCA-competent triple-negative breast cancer cells. J Clin Oncol (2013) 31(15-Suppl):2613.
16. Kothandapani A, Dangeti VS, Brown AR, Banze LA, Wang XH, Sobol RW, et al. Novel role of base excision repair in mediating cisplatin cytotoxicity. J Biol Chem (2011) 286(16):14564-74. doi:10.1074/jbc.M111.225375
17. Robu M, Shah RG, Petitclerc N, Brind'Amour J, Kandan-Kulangara F, Shah GM. Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc Natl Acad Sci U S A (2013) 110(5):1658-63. doi:10.1073/pnas.1209507110
18. Luijsterburg MS, Lindh M, Acs K, Vrouwe MG, Pines A, van Attikum H, et al. DDB2 promotes chromatin decondensation at UV-induced DNA damage. J Cell Biol (2012) 197(2):267-81. doi:10.1083/jcb.201106074
19. Pines A, Vrouwe MG, Marteijn JA, Typas D, Luijsterburg MS, Cansoy M, et al. PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1. J Cell Biol (2012) 199(2):235-49. doi:10.1083/jcb.201112132
20. Ghodgaonkar MM, Zacal NJ, Kassam SN, Rainbow AJ, Shah GM. Depletion of poly(ADP-ribose)polymerase-1 reduces host cell reactivation for UV-treated adenovirus in human dermal fibroblasts. DNA Repair (Amst) (2008) 7:617-32. doi:10.1016/j.dnarep.2008.01.001
21. Helleday T, Bryant HE, Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle (2005) 4(9):1176-8. doi:10.4161/cc.4.9.2031
22. Magan N, Isaacs RJ, Stowell KM. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells. Anticancer Drugs (2012) 23(6):627-37. doi:10.1097/CAD.0b013e328350900f
23. Mason KA, Valdecanas D, Hunter NR, Milas L. INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs (2008) 26(1):1-5. doi:10.1007/s10637-007-9072-5
24. Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer (2009) 101(2):256-62. doi:10.1038/sj.bjc.6605166
25. Bang Y-J, Im S-A, Lee K-W, Cho JY, Song E-K, Lee KH, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. J Clin Oncol (2013) 31(15-Suppl):4013.
26. Ahel I, Ahel D, Matsusaka T, Clark AJ, Pines J, Boulton SJ, et al. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature (2008) 451(7174):81-5. doi:10.1038/nature06420
27. Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K, et al. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation. J Biol Chem (2012) 287(16):12975-84. doi:10.1074/jbc.M111.321828
28. Zhao S, Coleman I, Coleman R, Nelson P. Association of PARP inhibitors and docetaxel resistance through suppressing a tumor microenvironment-associated secretory program. J Clin Oncol (2013) 31(15-Suppl):e22212.
29. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer (2007) 43(14):2124-33. doi:10.1016/j.ejca.2007.07.010
30. Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer (2008) 44(9):1302-14. doi:10.1016/j.ejca.2008.03.019
31. Rodríguez MI, Peralta-Leal A, O'Valle F, Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet (2013) 9(6):e1003531. doi:10.1371/journal.pgen.1003531
32. McPhee TR, McDonald PC, Oloumi A, Dedhar S. Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev Dyn (2008) 237(10):2737-47. doi:10.1002/dvdy.21685
33. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 30(3):283-8. doi:10.1038/nbt.2121
34. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res (2010) 70(20):7970-80. doi:10.1158/0008-5472.CAN-09-4521
35. Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. Curr Cancer Drug Targets (2010) 10(4):368-83. doi:10.2174/156800910791208571
36. Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A (2011) 108(2):745-50. doi:10.1073/pnas.1016538108
37. Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J (2003) 22(9):2255-63. doi:10.1093/emboj/cdg206
38. Zampieri M, Guastafierro T, Calabrese R, Ciccarone F, Bacalini MG, Reale A, et al. ADP-ribose polymers localized on Ctcf-Parp1-Dnmt1 complex prevent methylation of Ctcf target sites. Biochem J (2012) 441(2):645-52. doi:10.1042/BJ20111417
39. Simbulan-Rosenthal CM, Haddad BR, Rosenthal DS, Weaver Z, Coleman A, Luo R, et al. Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci U S A (1999) 96(23):13191-6. doi:10.1073/pnas.96.23.13191
40. Halappanavar S, Shah GM. Defective control of mitotic and post-mitotic checkpoints in Poly(ADP-ribose) polymerase-1(-/-) fibroblasts after mitotic spindle disruption. Cell Cycle (2004) 3(3):335-42. doi:10.4161/cc.3.3.670
41. Tong WM, Yang YG, Cao WH, Galendo D, Frappart L, Shen Y, et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene (2006) 26(26):3857-67. doi:10.1038/sj.onc.1210156